Münch group describes coronavirus infection & potential therapies.
SARS-CoV-2 infection profile and therapeutic strategies.
Complementing conventional antibiotics: Frankfurt scientists reveal atomic details for one of Legionella’s enzymatic weapons and develop first inhibitor.
Researchers from IBC2 and BMLS have now made a major step to a better understanding of the genes causing ALS
17 May 2022
IBC2 group leader Christian @MuenchLab featured in @J_Cell_Sci as cell scientist to watch! https://t.co/vay5QSVwcP
29 Apr 2022
Interested in #autophagy, #ubiquitin, #proteostasis & further Quality Control in Life Processes? Register now for t… https://t.co/BrlqDbHRQv
28 Apr 2022
A great opportunity to explore #Cancer cell signaling: Register now for the #EMBOcellSignaling Workshop in Cavtat,… https://t.co/JTww6HppVL
26 Apr 2022
Congratulations to IBC2 director @iDikic2 for his 3rd #ERCAdG🥳 His topic: ER-remodelling by ER-phagy. Congratulatio… https://t.co/PN9ryQrsYf
FOLLOW ON TWITTER